WIDAPLIK is a proprietary single pill combination of three medicines: telmisartan, amlodipine and indapamide and is available in three doses: a standard dose and two low doses. It is the first and ...

Widaplik is a single tablet, triple combination therapy for hypertension that is expected to be available in the fourth quarter of 2025. The Food and Drug Administration (FDA) has approved ...

WIDAPLIK is a proprietary single pill combination of three medicines: telmisartan, amlodipine and indapamide and is available in three doses: a standard dose and two low doses. It is the first and ...

Find lists of blood pressure medications commonly used to treat hypertension and the names of medications prescribed less often.

HELSINKI, Finland—In Ghana, survivors of a recent stroke who had hypertension experienced significant improvements in blood pressure control with a simple, mobile-health (mHealth) intervention led by ...

The drug combines established high blood pressure meds telmisartan, amlodipine and indapamide and is the first triple-combination therapy to boast a label from the FDA that allows its use as an ...

Zilebesiran continued to reduce SBP through 6 months in the indapamide and amlodipine subgroups, with only limited effects in the olmesartan subgroup. Serious adverse events rates were similar ...

The triple therapy polypill is contraindicated in patients with anuria or hypersensitivity to telmisartan, amlodipine, indapamide, sulfonamide-derived drugs or any individual component of the pill ...

Objective: The aim of this study was to compare the antihypertensive efficacy and tolerability of the calcium channel antagonist amlodipine besylate versus the angiotensin II type 1 receptor ...